Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The company plans to raise US $ 15 million
Tourmaline is now an indirect wholly owned subsidiary of Novartis
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Final decision from the European Commission is anticipated within the coming months
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Subscribe To Our Newsletter & Stay Updated
